Nelson Vergel
Founder, ExcelMale.com
I am trying to get a formulation combining these four compounds in an intranasal form.
Tadalafil:
Similar to sildenafil, tadalafil, another PDE5 inhibitor, has also been investigated for intranasal delivery. Studies have shown that intranasal tadalafil can rapidly reach systemic circulation, leading to a quicker onset of action compared to oral tadalafil. This route of administration may offer advantages for patients who desire more spontaneous sexual activity.
Apomorphine:
Apomorphine is a non-selective dopamine agonist that has shown potential as an intranasal therapy for ED. It acts by stimulating dopamine receptors in the brain, enhancing the release of nitric oxide, and promoting penile smooth muscle relaxation. Intranasal apomorphine has demonstrated promising results in improving erectile function, particularly in patients with neurogenic ED or those who do not respond well to PDE5 inhibitors.
Melanocortin receptor agonists:
Melanocortin receptor agonists, such as bremelanotide, have been investigated for their potential in treating ED. Intranasal bremelanotide acts on the central nervous system to promote sexual arousal and improve erectile function. Clinical trials have shown positive outcomes in terms of increased sexual desire and improved erectile function in patients with ED.
Oxytocin:
Oxytocin, a hormone involved in social bonding and sexual behavior, has been studied for its potential role in the treatment of ED. Intranasal oxytocin administration has shown promise in improving sexual function, desire, and satisfaction in both men and women. It may have a positive impact on psychogenic and functional ED.
Tadalafil:
Similar to sildenafil, tadalafil, another PDE5 inhibitor, has also been investigated for intranasal delivery. Studies have shown that intranasal tadalafil can rapidly reach systemic circulation, leading to a quicker onset of action compared to oral tadalafil. This route of administration may offer advantages for patients who desire more spontaneous sexual activity.
Apomorphine:
Apomorphine is a non-selective dopamine agonist that has shown potential as an intranasal therapy for ED. It acts by stimulating dopamine receptors in the brain, enhancing the release of nitric oxide, and promoting penile smooth muscle relaxation. Intranasal apomorphine has demonstrated promising results in improving erectile function, particularly in patients with neurogenic ED or those who do not respond well to PDE5 inhibitors.
Melanocortin receptor agonists:
Melanocortin receptor agonists, such as bremelanotide, have been investigated for their potential in treating ED. Intranasal bremelanotide acts on the central nervous system to promote sexual arousal and improve erectile function. Clinical trials have shown positive outcomes in terms of increased sexual desire and improved erectile function in patients with ED.
Oxytocin:
Oxytocin, a hormone involved in social bonding and sexual behavior, has been studied for its potential role in the treatment of ED. Intranasal oxytocin administration has shown promise in improving sexual function, desire, and satisfaction in both men and women. It may have a positive impact on psychogenic and functional ED.